Methicillin-resistant Staphylococcus aureus (MRSA)

The Pathogen

Known as a “superbug,” MRSA or Methicillin-resistant Staphylococcus aureus is gaining increased attention as an emerging infectious disease. The CDC estimates there are more than 126,000 MRSA infections each year in U.S. hospitals, and more than 5,000 deaths. This highly pathogenic bacteria is a major threat to patients who are hospitalized with open wounds, weakened immune systems and those who rely on invasive devices such as catheters or breathing tubes for treatment.

As its name implies, MRSA is a strain of Staphylococcus aureus that is resistant to commonly used antibiotics, such as various penicillins (methicillin, dicloxacillin, nafcillin etc.) and cephalosporin. Such resistance makes it extremely difficult to treat MRSA. Infections in patients with weakened immune systems or who have recently undergone surgery are potentially fatal. Therefore, expedient testing and diagnosis is essential to reducing fatalities and mitigating future infection.

The Problem

Conventional diagnosis of MRSA relies on body fluid Petri cultures grown in the lab. These can typically take 24-48 hours to return results. Since any delay in treating this type of infection can have fatal consequences, initial antibiotic treatment is often based upon 'strong suspicion' by the treating physician.

Laboratories around the world are under increased pressure to detect and identify MRSA faster, since the practice of administering antibiotics to patients who turn out to not have MRSA infections leads to increased MRSA antibiotic resistance. Rapid detection techniques such as Real-time PCR are increasingly used to diagnose MRSA. Unfortunately, the expense of the equipment and training needed for these advanced techniques remain prohibitive for many laboratory facilities.

The NanoLogix Solution - Live-threat microorganism detection of MRSA in 6 Hours

Using advanced and cost-effective Petri-dish methods, NanoLogix MRSA Quick Tests provide rapid detection and identificaiton of live-cell MRSA in as little as 6 hours. These results were recently validated by Dr. Jonathon Faro at the University of Texas Health Science Center.  To view a video of Dr. Faro’s results, click here.  

This significant decrease in waiting time translates to life-saving measures for patients, since delays in treatment can result in death. In addition, 6-hour “same-shift” results for hospital laboratories help to decrease the risk of technician error. Finally, in the likelihood of a MRSA outbreak, NanoLogix MRSA Quick Test Kits will help to mitigate the spread of the pathogenic bacteria to other patients through rapid and accurate detection and identification of MRSA.

 

NanoLogix